Project Grant R01CA296335
Award Date
1/1/25
Completion Date
12/31/29
Dollars Obligated
$584K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
New York, NY 10065, USA
Similar Awards
The National Cancer Institute awarded a $1,542,555 Project Grant to Sloan-Kettering Institute For Cancer Research under the Cancer Treatment Research program (CFDA 93.395). The grant will fund research from December 2022 through November 2027 to develop more effective treatments for localized bladder cancer. Specifically, the grantee will conduct genomic analyses of bladder cancer patient cohorts to validate DNA damage response mutations as predictors of sensitivity to bacillus Calmette-Guérin...
This Project Grant award from the National Cancer Institute (NCI), under the Cancer Cause and Prevention Research federal grant program (CFDA 93.393), provides $514,582 to the University of North Carolina at Chapel Hill to support research on targeting the APOBEC3 enzyme in bladder cancer. The research aims to better understand APOBEC3's role in bladder tumor development and progression, particularly its impact on squamous differentiation and potential for treatment resistance. Key objectives...
This federal Project Grant award from the National Cancer Institute (NCI), under the Cancer Cause and Prevention Research program (CFDA 93.393), provides $953,982 to The Trustees of Columbia University in the City of New York to investigate mechanisms of tumor plasticity in human bladder cancer. The research aims to elucidate the mechanistic basis for the phenotypic switch between luminal and basal subtypes of bladder tumors, which is associated with disease progression and therapeutic response....
This federal Project Grant award, issued by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), supports research at New York University School of Medicine to investigate the molecular mechanisms underlying the adeno-to-squamous transition in non-small cell lung cancer treatment. The $703,410 award, with a project period from January 16, 2025 to December 31, 2029, aims to identify vulnerabilities in the chromatin regulators driving this adaptive...
This federal Project Grant award of $708,000.00 provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research conducted by the Sloan-Kettering Institute for Cancer Research, a non-profit organization located in New York, NY. The research project is focused on investigating the "Prevalence and Biologic Impact of FGFR3 Genomic Alterations in Bladder Cancer". The 2-year award period runs from September 15, 2023 to...
The federal Project Grant award of $581,381 from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) supports research by the Sloan-Kettering Institute for Cancer Research to investigate the role of microhomology-mediated end-joining (MMEJ) in mitosis and its impact on drug resistance. The research aims to better understand DNA damage repair pathways and how they contribute to genomic instability and cancer development, with the goal of...
This Project Grant award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) provides $684,877 to the Icahn School of Medicine at Mount Sinai to conduct a multi-scale analysis of the tumor microenvironment in non-muscle invasive bladder cancer (NMIBC) to identify new therapeutic targets for overcoming Bacillus Calmette-Guerin (BCG) resistance. The study will generate high-resolution single-cell, spatial, and bulk transcriptomic data from 36 pre- and post-BCG treatment...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides funding to the Sloan-Kettering Institute for Cancer Research to investigate mechanisms through which deficiency of the SMARCA4 gene promotes metastasis in lung adenocarcinoma. The research aims to elucidate the role of the ROR2/p-GSK3bS9 signaling pathway in driving metastasis in SMARCA4-deficient lung cancer. Key activities include conducting RNA-seq, ChIP-seq, ATAC-seq, and mass...
This federal Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) provides $712,735 to the University of Southern California to conduct a phase II clinical trial investigating the combination of the EphrinB2 inhibitor SEPHB4-HSA and the PD-1 antibody Pembrolizumab for the treatment of muscle invasive bladder cancer (MIBC). The key objectives are to determine the clinical outcomes, pathological complete response rates, and recurrence-free...
This $238,722 Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) will support research at the Sloan-Kettering Institute for Cancer Research to investigate the role of mutagenic DNA repair in the persistence and acquired drug resistance of cancer cells. The key objectives of the 3-year project are to: (1) study persistence in response to PARP inhibitor treatment of BRCA1/2-mutant cancer cells; (2) examine mechanisms of mutagenic DNA repair in...